8:15 am Chair’s Opening Remarks
Exploring the Therapeutic Modalities of ARDS: The Trials & Tribulations of the ARDS Drug Development Landscape
8:20 am Discussing Vilobelimab Phase III Study in Severe COVID-19
Synopsis
- Reviewing how complement fragment C5a is activated by SARS-CoV-2 infection leading to neutrophil activation, reactive oxygen species generation, NETosis, release of tissue factor and fibrin formation, which contributes to a microangiopathy with thrombosis
- Exploring Vilobelimab, a first-in-class anti-C5a monoclonal antibody, binds C5a with high affinity clearing it from circulation
- Evaluating how Phase III results in severely ill, intubated COVID-19 patients demonstrate that vilobelimab has a clinically meaningful benefit reducing allcause 28-day mortality with a safety profile similar to standard-of-care
8:45 am Unlocking Multiple Mechanisms of Action Using a Unique AI/ML Platform with Novel Immunomodulators for ARDS Patients
Synopsis
- Highlighting the lead compound is Phase 2 ready for ARDS patients (including COVID-ARDS) having completed Phase 1
- Using the unique AI/ML platform to develop 21 next generation p38 alpha/MK2 novel immunomodulators
9:10 am Exploring the IV NK1R+ MSC in Acute Respiratory Distress Syndrome
Synopsis
- Understanding MSCs for ARDS
- Discussing the phase I/II trial design
- Reviewing the therapeutic strategy in ARDS
9:35 am Morning Break & Networking
10:30 am Interactive Roundtable Discussions Mechanisms of Action, Research Progress, Challenges & Opportunities
Synopsis
This session will facilitate in-depth discussion between participants around your chosen therapeutic approach, discussing
- Monoclonal Antibody Therapy
- Anti-Viral Therapy
- IV Alpha-1 Antitrypsin Therapy
- Mesenchymal Stem Cells
- Complement
- Neutrophil Extracellular Traps
- mRNA / sRNA / CRISPR Techniques
- Manipulating Ion Channels in ARDS
Harnessing Innovative Technology for ARDS Research & Drug Discovery
11:15 am Colonic Oxygen Microbubble Augment Systemic Oxygenation & CO2 Removal in a Porcine Smoke in Porcine Smoke Inhalation Model of Severe Hypoxia
Synopsis
- Highlighting colonic and intraperitoneal oxygen microbubbles increase arterial (PaO2), mixed venous (PmvO2) blood oxygen gas pressures, and peripheral oxygen saturation (SpO2); in acutely hypoxic pigs suffering from respiratory failure
- Discussing how colonic and intraperitoneal oxygen microbubbles decrease arterial (PaCO2) and mixed venous (PmvCO2) blood carbon dioxide gas pressures; in acutely hypoxic pigs suffering from respiratory failure
- Reviewing how cytokines IL-1B and IL-6 were lower for oxygen microbubbletreated animals than for non-treated animals
11:45 am Networking Lunch
Discover the Similarities & Differences Between COVID ARDS & Non-COVID ARDS: Reimagining the ARDS Drug Development Path
12:45 pm Clinical Development of Solnatide Peptide for the Therapeutic Treatment of ARDS During the Coronavirus Pandemic
Synopsis
- Reviewing solnatide peptide and its capacity to activate pulmonary edema clearance and highlighting the molecular structure and interaction with the pulmonary ENaC channel
- Exploring basic characteristics of ARDS patients Vs. COVID-19 patients to illuminate whether ARDS pneumonia behaves similarly to viral/COVID pneumonia
- Navigating the limitation in hospital management during pandemics
- Delving into clinical trials to explore what lessons can be taken away from the pandemic
1:10 pm Going Beyond the Molecule: The Multi-Factorial Causes of ARDS & COVID-19 ARDS as a Challenge for Drug Development
Synopsis
- Reviewing the multiple elements that can lead to ARDS and COVID-ARDS, to better understand the targets to pursue to achieve therapeutic impact
- Using the improving knowledge of COVID-19 ARDS to increase the number of pharmacological targets and therapeutic candidates for ARDS
1:35 pm Afternoon Break & Networking
2:05 pm Pathway to a New Therapy to Save Lives: Differences & Similarities to Sepsis-Related ARDS
Synopsis
- Examining the molecular science that led up to initiating trials of intravenous vitamin C in a patient with sepsis acute ARDS
- Highlighting translatability from each related-ARDS syndrome to consolidate understandings of ARDS treatment and physiology
2:30 pm Repurposing Immunomodulatory Drugs for COVID-19 ARDS: Leukine for COVID-19 with Acute Hypoxemia
Synopsis
- Highlighting the immunomodulatory effects of GM-CSF in pulmonary diseases
- Reviewing the clinical data from COVID-19 studies